SA
SGMO

Sicart Associates’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Sicart Associates’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10,460
Closed -$157K – 100
2017
Q3 		$157K Sell
10,460
-200
-2% -$2.21K 0.11% 73
2017
Q2 		$94K Buy
+10,660
New +$68.4K 0.07% 77
2017
Q1 		– Sell
-101,950
Closed -$311K – 102
2016
Q4 		$311K Buy
+101,950
New +$371K 0.21% 87

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sicart Associates's SGMO Position: Q4 2017 in Review

Sicart Associates sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2017, closing a stake of 10,460 shares — an estimated $157K sold.

Sicart Associates first reported a position in SGMO in Q4 2016 and held it in 3 quarters. The position peaked at $311K in Q4 2016. 170 funds tracked by Wall St. Rank hold SGMO as of Q4 2017.

  • Sicart Associates reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2017 after selling out during the quarter.
  • Sicart Associates sold 10,460 SANGAMO THERAPEUTICS INC shares in Q4 2017, an estimated $157K.
  • Sicart Associates first reported a position in SANGAMO THERAPEUTICS INC in Q4 2016 and held it in 3 quarters.
  • Sicart Associates's SANGAMO THERAPEUTICS INC position peaked at $311K in Q4 2016.
  • 170 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2017.

Based on Sicart Associates's 13F filing for Q4 2017, filed 17 Jan 2018.